Financial Data and Key Metrics Changes - For fiscal 2025, total company revenue increased by 9% at constant currency rates and 7% on a reported basis compared to 2024, reaching EUR 1.26 billion to EUR 1.29 billion for 2026 guidance [5][25] - Gross profit margin rose by 160 basis points compared to 2024, with Q4 gross profit margin increasing by 120 basis points to 30.9% [7][18] - Net profit for Q4 totaled EUR 47.6 million, with diluted earnings per share at EUR 0.17 [19] Business Line Data and Key Metrics Changes - The Biopharmaceutical and Diagnostic Solutions (BDS) segment delivered double-digit growth, with revenue increasing by 13% at constant currency and 10% on a reported basis in Q4 [17][20] - Revenue from high-value solutions grew 31% to EUR 171 million in Q4, representing approximately 49% of total company revenue for the quarter [18][20] - Engineering segment revenue decreased by 23% to EUR 39.4 million in Q4 due to lower revenue in glass conversion and assembly [21] Market Data and Key Metrics Changes - Revenue from GLP-1s accounted for approximately 19%-20% of total company revenue in 2025, growing more than 50% compared to 2024 [9] - The company expects GLP-1s to serve as a meaningful tailwind as patient demand continues to grow, with a projected mid-teens growth rate for 2026 [32][49] - Biologics represented 41% of BDS revenues in 2025, up from 34% in 2024, indicating a growing market presence [11] Company Strategy and Development Direction - The company is focused on high-value solutions and has invested in expanding capacity for high-value syringes in Fishers, Indiana, and Latina, Italy [8][12] - The strategy includes pivoting away from non-high-value product categories and increasing participation in other injectable biologics [7][11] - The company aims to align growth investments with customer demand trends and capitalize on the evolving market for injectable biologics and biosimilars [16][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the robust demand for biologics and the company's ability to meet this demand through its integrated value proposition and innovative products [27] - The company anticipates continued operational progress and productivity gains, particularly in the engineering segment, to support long-term sustainable growth [28] - Management acknowledged challenges in the engineering segment due to lower order intake but remains optimistic about future opportunities [15][35] Other Important Information - The company ended fiscal 2025 with cash and cash equivalents of EUR 130.6 million and net debt of EUR 337.7 million, indicating a solid liquidity position [23] - Capital expenditures for 2025 totaled EUR 294.9 million, with approximately 89% allocated for growth projects [24] Q&A Session Summary Question: Expectations for GLP-1 growth in 2026 - Management expects GLP-1 revenue growth in the mid-teens for 2026, consistent with previous growth rates [32] Question: Insights on engineering segment order intake - Management noted that the sales cycle for engineering projects is longer than anticipated, impacting order intake, but the pipeline remains healthy [35] Question: Capacity constraints for high-value solutions - Management confirmed that capacity constraints exist but are being addressed through ramping up production in Fishers and Latina [40] Question: Drivers of margin expansion - Management highlighted that margin expansion will be driven by a favorable product mix and operational improvements in new facilities [44] Question: Long-term growth outlook for GLP-1s - Management believes GLP-1s will continue to be a significant growth driver, although the exact configuration of the market remains uncertain [49] Question: Performance of other biologic categories - Management indicated strong performance in monoclonal antibodies and other biologics, with a focus on injectable formats [75]

Financial Data and Key Metrics Changes - In Q2 2025, revenue increased by 8% to $280 million, driven by a 10% growth in the BDS segment, offsetting a 2% decline in the Engineering segment [16][19] - Adjusted EBITDA rose to $65.1 million, resulting in an adjusted EBITDA margin of 23.2% for 2025, a 240 basis point improvement [18][22] - Net profit totaled $29.7 million, with diluted earnings per share of $0.11, while adjusted net profit was $31.3 million with adjusted diluted EPS also at $0.11 [18][22] Business Line Data and Key Metrics Changes - BDS segment revenue grew 10% to $243.5 million, with high value solutions accounting for 42% of total revenue, driven by strong demand for high value syringes [19][20] - Engineering segment revenue decreased by 2% to $36.5 million, with gross profit margin declining to 6.6% due to a higher mix of legacy projects [20][21] - High value solutions revenue increased by 13% to $116.8 million, primarily from high value syringes, easy fill cartridges, and easy fill vials [17][19] Market Data and Key Metrics Changes - Biologics represented 39% of BDS revenue in 2025, up from 25% in the same periods of fiscal 2024 and 2023 [13] - The company is experiencing stabilization in vial demand as destocking effects ease, with a projected mid to high single-digit growth for vials in 2025 [36][38] - The company anticipates continued strong demand due to trends such as the increase in self-administration of medicine and the rise in biologics [10][27] Company Strategy and Development Direction - The company is focused on executing its multiyear investment optimization plans, enhancing commercial strategy, and positioning itself for long-term growth opportunities [26][27] - The company is evaluating a second location in Bologna, Italy, to support its innovation hub and optimize its footprint [9][10] - The strategic focus remains on high value solutions, with expectations of continued strong demand in the biologics market [10][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year guidance, citing healthy market demand and operational improvements [26][27] - The company is well-positioned to benefit from onshoring initiatives announced by several pharma and biotech customers, particularly in the U.S. [100] - Management noted that the biologics market is heavily investing in new technology, indicating strong future demand [33][51] Other Important Information - The company announced a $200 million financing to support expansion in syringe production and capacity for ready-to-use cartridges [22][46] - Capital expenditures totaled $69.1 million for 2025, with a significant year-over-year improvement in free cash flow [22] - The company reiterated its fiscal 2025 guidance, expecting revenue between $1.16 billion and $1.19 billion [23] Q&A Session Summary Question: Are delays in new orders related to customer decision-making due to tariffs? - Management clarified that delays are primarily due to timing and customer CapEx decision-making, not lost negotiations [30][32] Question: Is there continued improvement in vial demand? - Management confirmed a 3% increase in vial demand compared to the same period last year, with confidence in mid to high single-digit growth for 2025 [36][38] Question: Are tariffs impacting customer behavior? - Management indicated that they have not seen significant pull-forward behavior due to tariffs and have been able to offset tariff impacts through customer conversations and leveraging their global footprint [42][45] Question: What is the expected growth trajectory for the Engineering segment? - Management expects a rebound in growth and margins in the Engineering segment as legacy projects are completed and new contracts are secured [74][76] Question: How is the company positioned to benefit from onshoring initiatives? - Management noted that they are seeing increased interest from clients in the U.S. for engineering offerings and technology sales due to onshoring strategies [100][101]